227 related articles for article (PubMed ID: 9617594)
21. New approaches to the systemic treatment of melanoma.
Chowdhury S; Vaughan MM; Gore ME
Cancer Treat Rev; 1999 Oct; 25(5):259-70. PubMed ID: 10544070
[TBL] [Abstract][Full Text] [Related]
22. Systemic therapy in melanoma.
Nathan FE; Mastrangelo MJ
Semin Surg Oncol; 1998 Jun; 14(4):319-27. PubMed ID: 9588725
[TBL] [Abstract][Full Text] [Related]
23. Single-agent interleukin-2 in the treatment of metastatic melanoma.
Petrella T; Quirt I; Verma S; Haynes AE; Charette M; Bak K;
Curr Oncol; 2007 Feb; 14(1):21-6. PubMed ID: 17576460
[TBL] [Abstract][Full Text] [Related]
24. Combined treatment of metastatic melanoma with interferons and cytotoxic drugs.
Garbe C; Kreuser ED; Zouboulis CC; Stadler R; Orfanos CE
Semin Oncol; 1992 Apr; 19(2 Suppl 4):63-9. PubMed ID: 1372765
[TBL] [Abstract][Full Text] [Related]
25. Immune modulations during chemoimmunotherapy & novel vaccine strategies--in metastatic melanoma and non small-cell lung cancer.
Iversen TZ
Dan Med J; 2013 Dec; 60(12):B4774. PubMed ID: 24355457
[TBL] [Abstract][Full Text] [Related]
26. [Chemotherapy of malignant melanoma--current status].
Karg C; Garbe C; Orfanos CE
Hautarzt; 1990 Feb; 41(2):56-65. PubMed ID: 2180855
[TBL] [Abstract][Full Text] [Related]
27. Similar efficacy for phase I trials in comparison with DTIC for advanced malignant melanoma: an analysis of melanoma outcomes in CTEP-sponsored phase I trials 1995-2011.
Luke JJ; Rubinstein LV; Smith GL; Ivy SP; Harris PJ
Melanoma Res; 2013 Apr; 23(2):152-8. PubMed ID: 23411478
[TBL] [Abstract][Full Text] [Related]
28. Multiinstitutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma.
Atkins MB; O'Boyle KR; Sosman JA; Weiss GR; Margolin KA; Ernest ML; Kappler K; Mier JW; Sparano JA; Fisher RI
J Clin Oncol; 1994 Aug; 12(8):1553-60. PubMed ID: 8040667
[TBL] [Abstract][Full Text] [Related]
29. [Adjuvant therapy of malignant melanoma].
Franke W; Neumann NJ; Ruzicka T; Schulte KW
Praxis (Bern 1994); 2001 Feb; 90(8):301-6. PubMed ID: 11256332
[TBL] [Abstract][Full Text] [Related]
30. Development and results of biochemotherapy in metastatic melanoma: the University of Texas M.D. Anderson Cancer Center experience.
Legha SS; Ring S; Eton O; Bedikian A; Plager C; Papadopoulos N
Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S9-15. PubMed ID: 9457387
[TBL] [Abstract][Full Text] [Related]
31. Medical treatment of metastatic melanoma.
Houghton AN; Meyers ML; Chapman PB
Surg Clin North Am; 1996 Dec; 76(6):1343-54. PubMed ID: 8977555
[TBL] [Abstract][Full Text] [Related]
32. Oblimersen: Augmerosen, BCL-2 antisense oligonucleotide - Genta, G 3139, GC 3139, oblimersen sodium.
Drugs R D; 2007; 8(5):321-34. PubMed ID: 17767397
[TBL] [Abstract][Full Text] [Related]
33. Biochemotherapy with carmustine, cisplatin, dacarbazine, tamoxifen and low-dose interleukin-2 for patients with metastatic malignant melanoma.
Su PJ; Chen JS; Liaw CC; Chang HK; Wang HM; Yang TS; Lin YC; Liau CT; Yang HY; Yeh KY; Ho MM; Chang NJ; Wang CH; Chang JW
Chang Gung Med J; 2011; 34(5):478-86. PubMed ID: 22035892
[TBL] [Abstract][Full Text] [Related]
34. Bacillus Calmette-Guérin immunotherapy in combination with DTIC (NSC-45388) for the treatment of malignant melanoma.
Gutterman JU; Mavligit GM; Reed R; Burgess MA; Gottlieb J; Hersh EM
Cancer Treat Rep; 1976 Feb; 60(2):177-82. PubMed ID: 769970
[TBL] [Abstract][Full Text] [Related]
35. DTIC vs. IFN-alpha plus DTIC in the treatment of patients with metastatic malignant melanoma.
Rudolf Z; Strojan P
Neoplasma; 1996; 43(2):93-7. PubMed ID: 8843969
[TBL] [Abstract][Full Text] [Related]
36. Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b.
Rosenberg SA; Yang JC; Schwartzentruber DJ; Hwu P; Marincola FM; Topalian SL; Seipp CA; Einhorn JH; White DE; Steinberg SM
J Clin Oncol; 1999 Mar; 17(3):968-75. PubMed ID: 10071291
[TBL] [Abstract][Full Text] [Related]
37. Treatment for metastatic malignant melanoma: old drugs and new strategies.
Mouawad R; Sebert M; Michels J; Bloch J; Spano JP; Khayat D
Crit Rev Oncol Hematol; 2010 Apr; 74(1):27-39. PubMed ID: 19781957
[TBL] [Abstract][Full Text] [Related]
38. Overall and progression-free survival in metastatic melanoma: analysis of a single-institution database.
Khan MA; Andrews S; Ismail-Khan R; Munster PN; Brem S; King J; Reintgen DS; Sondak VK; Daud AI
Cancer Control; 2006 Jul; 13(3):211-7. PubMed ID: 16885917
[TBL] [Abstract][Full Text] [Related]
39. [Anorectal malignant melanomas. Apropos of 5 cases. Review of the literature].
Melhouf MM; el Amrani N; Mathieu-Daude H; Dubois JB
Ann Gastroenterol Hepatol (Paris); 1995 Sep; 31(4):209-12. PubMed ID: 7486817
[TBL] [Abstract][Full Text] [Related]
40. (Neo)adjuvant systemic therapy for melanoma.
van Zeijl MC; van den Eertwegh AJ; Haanen JB; Wouters MW
Eur J Surg Oncol; 2017 Mar; 43(3):534-543. PubMed ID: 27453302
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
